AllianceBernstein’s Cardiff Oncology CRDF Stock Holding History

AllianceBernstein’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-48,730	Closed	-$137K	–	3338
2026 Q1	$137K	Sell	48,730 -7	-0%	-$14	﹤0.01%	3131
2025 Q4	$137K	Buy	48,737 +7	+0%	+$16	﹤0.01%	3139
2025 Q3	$100K	Hold	48,730	–	–	﹤0.01%	3179
2025 Q2	$154K	Buy	48,730 +38,350	+369%	+$117K	﹤0.01%	3109
2025 Q1	$32.6K	Hold	10,380	–	–	﹤0.01%	3163
2024 Q4	$45K	Hold	10,380	–	–	﹤0.01%	3192
2024 Q3	$27.7K	Hold	10,380	–	–	﹤0.01%	3210
2024 Q2	$23K	Buy	+10,380	New	+$39.1K	﹤0.01%	3221
2017 Q2	–	Sell	-146	Closed	-$12K	–	3150
2017 Q1	$12K	Hold	146	–	–	﹤0.01%	2986
2016 Q4	$22K	Hold	146	–	–	﹤0.01%	3008
2016 Q3	$47K	Sell	146 -44	-23%	-$16K	﹤0.01%	2958
2016 Q2	$62K	Buy	+190	New	+$65.4K	﹤0.01%	2941
2014 Q2	–	Sell	-3	Closed	-$1K	–	3444
2014 Q1	$1K	Hold	3	–	–	﹤0.01%	3521
2013 Q4	$1K	Hold	3	–	–	﹤0.01%	3322
2013 Q3	$1K	Buy	+3	New	+$1.71K	﹤0.01%	3351

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein's CRDF Position: Q2 2026 in Review

AllianceBernstein sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 48,730 shares — an estimated $137K sold.

AllianceBernstein first reported a position in CRDF in Q3 2013 and held it in 15 quarters. The position peaked at $154K in Q2 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

AllianceBernstein reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
AllianceBernstein sold 48,730 Cardiff Oncology shares in Q2 2026, an estimated $137K.
AllianceBernstein first reported a position in Cardiff Oncology in Q3 2013 and held it in 15 quarters.
AllianceBernstein's Cardiff Oncology position peaked at $154K in Q2 2025.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.